PKMYT1

Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting

Retrieved on: 
화요일, 3월 8, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Associate professor, PKMYT1, Genome, Company, Department, DDR, Therapy, LOF, MD Anderson Cancer Center, Institute, DNA, Atri, MBBS, Patient, FRCP, Ataxia–telangiectasia, ATR, Doctor of Philosophy, Neoplasm, STEP2, Division, CRISPR, View, Pharmaceutical industry, Medical imaging, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

Repares platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

Key Points: 
  • Repares platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006230/en/

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
화요일, 3월 1, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, IPO, Research, D&O, Patient, AMF, Quarter, Forward-looking statement, Security (finance), DNA, Safety, PARP, U.S. Securities and Exchange Commission, Genome, Therapy, CRISPR, FOLFIRI, Company, STEP2, COVID-19, ATR, Neoplasm, Clinical trial, IND, Parpi, Risk, PKMYT1, Insurance, ATM, Net, Pharmaceutical industry, Medical imaging, G&A, Reparenting, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021.
  • 2021 Highlights and 2022 Outlook:
    Initial Phase 1 results provided clinical proof of concept and validated Repares SNIPRx platform for molecular selection of tumors for therapy with RP-3500.
  • Fourth Quarter and Full Year 2021 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of December 31, 2021 were $341.9 million, including the proceeds from the follow-on public offering in November 2021.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Retrieved on: 
목요일, 2월 3, 2022
Biotechnology, Health, Oncology, Webcast, DNA, View, Therapy, CRISPR, Genome, Company, ATR, PKMYT1, Conference, Pharmaceutical industry, Video game

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February.
  • A replay of the webcast will be archived on the Companys website for 90 days.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005006/en/

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022

Retrieved on: 
금요일, 1월 7, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, Safety, COVID-19, AMF, Company, Patient, Webcast, Research, Forward-looking statement, STEP2, IND, DNA, PARP, Conference, U.S. Securities and Exchange Commission, Neoplasm, Treatment, Security (finance), FOLFIRI, Private Securities Litigation Reform Act, Risk, Parpi, SEC, PKMYT1, Genome, ATM, Achievement, CRISPR, ATR, Pharmaceutical industry, Tulsa Reparations Coalition

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.
  • Repare ended the third quarter of 2021 with approximately $268.2 million in cash and cash equivalents.
  • Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
    Repare Therapeutics will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

Retrieved on: 
수요일, 1월 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Safety, COVID-19, Baldwin Wallace University, Company, Patient, Forward-looking statement, DNA, Cancer, U.S. Securities and Exchange Commission, Pfizer, Security (finance), Commercial, Risk, Private Securities Litigation Reform Act, MBA, SEC, PKMYT1, Marketing, Genome, Chief commercial officer, CRISPR, Kellogg School, BA, ATR, Northwestern University, Pharmaceutical industry, Reparenting

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.
  • I am thrilled to join Repare at this exciting time in the Companys evolution, said Mr. Herman.
  • Mr. Herman joins Repare from Y-mAbs Therapeutics, where he served as Chief Commercial Officer and led the successful launch of DANYELZA (naxitamab).
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
월요일, 1월 3, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Therapy, Webcast, DNA, Genome, CRISPR, PKMYT1, Company, View, Conference, ATR, Pharmaceutical industry

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.
  • A live webcast of the presentation can be accessed in the Investor section of the Companys website at https://ir.reparerx.com/news-and-events/events .
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005258/en/

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors

Retrieved on: 
화요일, 12월 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, SL, Genome, Therapy, DNA, ATR, CRISPR, Neoplasm, CCNE1, Safety, MTD, PKMYT1, Company, Index (publishing), View, Patient, STEP2, Pharmaceutical industry, Reparenting, RP-6306, Repare Therapeutics, Inc., RP-6306, REPARE THERAPEUTICS, INC.

MAGNETIC will assess the safety and tolerability of RP-6306 in combination with gemcitabine.

Key Points: 
  • MAGNETIC will assess the safety and tolerability of RP-6306 in combination with gemcitabine.
  • It will enroll approximately 104 patients with tumors harboring genomic alterations that were identified through Repares proprietary STEP2 screens.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005195/en/

Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans

Retrieved on: 
수요일, 12월 15, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, CRISPR, Company, Participation, Securities Act of 1933, Genome, Business, Executive, Corporate development, ASDP Indonesia Ferry, Nasdaq, PKMYT1, ATR, Security (finance), DNA, Legislation, Mission statement, View, Online gambling, Pharmaceutical industry, Reparations for slavery

Under U.S. and Canadian securities laws and the Companys trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company.

Key Points: 
  • Under U.S. and Canadian securities laws and the Companys trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company.
  • Up to 328,681 common shares of Repare may be sold under the ASDPs implemented or modified by the Executives in the aggregate, and up to 95,320 common shares of Repare may be sold under the ASDPs implemented by the Other Insiders.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006112/en/

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Retrieved on: 
월요일, 11월 15, 2021
Other Health, Health, Genetics, Clinical Trials, Oncology, View, Therapy, Genome, Conference, Company, Webcast, PKMYT1, ATR, DNA, CRISPR, Pharmaceutical industry

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November.
  • A replay of the webcast will be archived on the Companys website for 90 days.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005190/en/

Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
수요일, 11월 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Net, BRCA2, Therapy, Security (finance), D, COVID-19, Acquisition, Circulating tumor DNA, Board of directors, Safety, Leadership, Research, AMF, Forward-looking statement, Review, U.S. Securities and Exchange Commission, Foundation Medicine, ATR, Patient, Amgen, Private Securities Litigation Reform Act, Neoplasm, CEO, RAD51C, STEP2, Risk, Anemia, PARP, SEC, PKMYT1, CDK12, DNA, CRISPR, RECIST, Genome, AACR, Board, Ono, Company, IPO, BRCA1, D&O, Genentech, ATM, Pharmaceutical industry, Medical imaging, Lithium, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021.
  • Third Quarter 2021 Review and Operational Updates:
    Early data showed RP-3500 appears safe and well tolerated.
  • Mr. Civik was most recently President and CEO of Five Prime Therapeutics until its $1.9 billion acquisition by Amgen in April 2021.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.